PD-L1 expression as a predictive biomarker in cancer immunotherapy

Patel, Sandip Pravin, Kurzrock, Razelle·2015·Molecular Cancer Therapeutics
DOI 10.1158/1535-7163.mct-14-0983

Cited by (1,001)

Items 301–400 of 1,001

  1. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti‐PD‐L1 antibody for treatment of triple‐negative breast cancer
    Prahlad V. Raninga, Andy Chao Hsuan Lee, Debottam Sinha, Yu‐Yin Shih, Deepak Mittal, Ashwini Makhale, Amanda Louise Bain, Devathri M. Nanayakkara, Kathryn Fay Tonissen, Murugan Kalimutho et al. · 2019 · International Journal of Cancer
  2. CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy
    Sasan Ghaffari, Nastaran Khalili, Nima Rezaei · 2021 · Journal of Experimental & Clinical Cancer Research
  3. Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies
    Ye Yang, Su Fang Wu, Wei Bao · 2023 · International Journal of Gynecology & Obstetrics
  4. PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue – prognostic implications and rationale for immunotherapy
    Melanie Boxberg, Katja Steiger, Ulrich Lenze, Hans Rechl, Rüdiger von Eisenhart‐Rothe, Klaus Wörtler, Wilko Weichert, Rupert Langer, Katja Specht · 2017 · OncoImmunology
  5. PD-L1 Expression and Survival among Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy
    Steffen Filskov Sorensen, Wei Zhou, Marisa P Dolled-Filhart, Jeanette Bæhr Georgsen, Zhen Wang, Kenneth Emancipator, Dianna Wu, Michael Busch-Sørensen, Peter Meldgaard, Henrik Hager · 2016 · Translational Oncology
  6. Prognostic value of tumor PD-L1 expression combined with CD8 + tumor infiltrating lymphocytes in high grade serous ovarian cancer
    Qiaohong Wang, Weihua Lou, Wen J. Di, Xia Wu · 2017 · International Immunopharmacology
  7. APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy
    Amélie Boichard, Timothy V. Pham, Huwate Yeerna, Aaron Michael Goodman, Pablo Tamayo, Scott Michael Lippman, Garrett Michael Frampton, Igor F. Tsigelny, Razelle Kurzrock · 2018 · OncoImmunology
  8. EZH2 regulates PD-L1 expression via HIF-1α in non-small cell lung cancer cells
    Yuetao Zhao, Xinxin Wang, Wei Wu, Haixia Long, Jiani Huang, Zhongyu Wang, Tao Li, Shu Tang, Bo Zhu, Degao Chen · 2019 · Biochemical and Biophysical Research Communications
  9. Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors
    Philipp Knopf, Dimitri Stowbur, Sabrina H. L. Hoffmann, Natalie Hermann, Andreas Maurer, Valentina Bucher, Marilena Poxleitner, Bredi Tako, Dominik Sonanini, Balaji Krishnamachary et al. · 2023 · Molecular Cancer
  10. Assessing PDL-1 and PD-1 in Non–Small Cell Lung Cancer: A Novel Immunoscore Approach
    Erna‐Elise Paulsen, Thomas Karsten Kilvaer, Mehrdad Rakaee, Samer Al‐Saad, Sigurd M. Hald, Sigve Andersen, Elin H. Richardsen, Nora Ness, Lill‐Tove Busund, Roy Martin Bremnes et al. · 2016 · Clinical Lung Cancer
  11. Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature
    Rui Bao, Yanpu Wang, Jianhao Lai, Hua Zhu, Yang Zhao, Suping Li, Nan Li, Jing Huang, Zhi Yang, Fan Wang et al. · 2018 · Molecular Pharmaceutics
  12. PRMT1 mediated methylation of cGAS suppresses anti-tumor immunity
    Jing Liu, Xia Bu, Chen Chu, Xiaoming Dai, John M. Asara, Piotr Siciński, Gordon James Freeman, Wenyi Wei · 2023 · Nature Communications
  13. Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia
    Matthias M. Weber, Christian Fottner · 2018 · Oncology Research and Treatment
  14. Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies
    Nicola L. Lawson, Carly I. Dix, Paul Scorer, Christopher J. Stubbs, Edmond Wong, Liam Hutchinson, Eileen J. McCall, Marianne Schimpl, Emma DeVries, Jill Walker et al. · 2019 · Modern Pathology
  15. Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma
    Jennifer Sun, Barbara Muz, Kinan Alhallak, Matea Markovic, Shannon Gurley, Zhe Wang, Nicole Guenthner, Katherine Wasden, Mark Aaron Fiala, Justin A. King et al. · 2020 · Cancers
  16. PD-1 and PD-L1 blockade in gastrointestinal malignancies
    Hazel Lote, Catherine Cafferkey, Ian Chau · 2015 · Cancer Treatment Reviews
  17. Is There a Role for Immunotherapy in Prostate Cancer?
    Alessandro Rizzo, Veronica Mollica, Alessia Cimadamore, Matteo Santoni, Marina Scarpelli, Francesca Giunchi, Liang Cheng C, Antonio Lopez-beltran B, Michelangelo Fiorentino, Rodolfo Montironi et al. · 2020 · Cells
  18. Immune Checkpoint Modulation in Colorectal Cancer: What’s New and What to Expect
    Julie Jacobs, Evelien Smits, Filip Lardon, Patrick Pauwels, Vanessa Deschoolmeester · 2015 · Journal of Immunology Research
  19. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma
    Yubo Jiang, Anthony W.I. Lo, Angela Wong, Wenfeng Chen, Yan Wang, Lin Li, Jianming Xu · 2017 · Oncotarget
  20. Current status and perspectives in immunotherapy for metastatic melanoma
    Riccardo Marconcini, for the Italian Melanoma Intergroup (IMI), Francesco Spagnolo, Luigia Stefania Stucci, Simone Ribero, Elena Marra, Francesco De Rosa, Virginia Picasso, Lorenza Di Guardo, Carolina Cimminiello et al. · 2017 · Oncotarget
  21. Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC
    Maria Bassanelli, Stefano Sioletic, Maurizio Martini, Silvana Giacinti, Antonella Viterbo, Anita Staddon, Fabrizio Liberati, Anna Ceribelli · 2018 · Anticancer Research
  22. PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system ?
    Cristina Raimondi, Guido Carpino, Chiara Nicolazzo, Angela Gradilone, Walter Gianni, Alain Jonathan Gelibter, Eugenio Gaudio, Enrico Cortesi, Paola Gazzaniga · 2017 · OncoImmunology
  23. The Interplay between Circulating Tumor Cells and the Immune System: From Immune Escape to Cancer Immunotherapy
    Kevin Leone, Cristina Poggiana, Rita Zamarchi · 2018 · Diagnostics
  24. Making Molecular Imaging a Clinical Tool for Precision Oncology
    David A. Mankoff, Michael D. Farwell, Amy Sanders Clark, Daniel A. Pryma · 2016 · JAMA Oncology
  25. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort
    Nora Ness, Sigve Andersen, Mehrdad Rakaee, Cecilie Valborg Nordbakken, Andrej Valkov, Erna‐Elise Paulsen, Yngve Nordby, Roy Martin Bremnes, Tom Dønnem, Lill‐Tove Busund et al. · 2017 · Oncotarget
  26. Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer
    Kyu Sang Lee, Yoonjin Kwak, Soyeon Ahn, Eun Hee Shin, Heung‐Kwon Oh, Duck‐Woo Kim, Sung‐Bum Kang, Gheeyoung Choe, Woo Ho Kim, Hye Seung Lee · 2017 · Cancer Immunology Immunotherapy
  27. PD-L1 Expression in Tumor Metastasis is Different Between Uveal Melanoma and Cutaneous Melanoma
    Asad Javed, David Arguello, Curtis Johnston, Zoran Gatalica, Mizue Terai, Ryan Michael Weight, Marlana M. Orloff, Michael J. Mastrangelo, Takami Sato · 2017 · Immunotherapy
  28. Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients
    Christina Jensen, Daniel Hargbøll Madsen, Morten Hansen, Henrik Schmidt, Inge Marie Svane, M.A. Karsdal, Nicholas Willumsen · 2018 · Journal for ImmunoTherapy of Cancer
  29. Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
    Jacob J. Adashek, Shumei Kato, Roberto Ferrara, Giuseppe Lo Russo, Razelle Kurzrock · 2019 · The Oncologist
  30. The Role of Exosomal microRNA in Cancer Drug Resistance
    Qiao-ru Guo, Hui Wang, Ying-da Yan, Yun Liu, Chaoyue Su, Hubiao Chen, Yan‐yan Yan, Rameshwar Adhikari, Qiang Wu, Jianye Zhang · 2020 · Frontiers in Oncology
  31. Applications of radiomics in precision diagnosis, prognostication and treatment planning of head and neck squamous cell carcinomas
    Stefan P. Haider, Barbara Ann Burtness, Wendell Gray Yarbrough, Seyedmehdi Payabvash · 2020 · Cancers of the Head & Neck
  32. Near Infrared Photoimmunotherapy; A Review of Targets for Cancer Therapy
    Takuya Kato, Hiroaki Wakiyama, Aki Furusawa, Peter L. Choyke, Hisataka Kobayashi · 2021 · Cancers
  33. Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer
    Xingyu Chen, Lixiang Feng, Yujing Huang, Yi Wu, Na Xie · 2022 · Cancers
  34. Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden
    Jan Budczies, Anja Seidel, Petros Christopoulos, Volker Endris, Matthias Kloor, Balázs Győrffy, Barbara Seliger, Peter Schirmacher, Albrecht Stenzinger, Carsten Denkert · 2018 · OncoImmunology
  35. Understanding PD-L1 Testing in Breast Cancer: A Practical Approach
    Ramona Erber, Arndt Hartmann · 2020 · Breast Care
  36. Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells
    Yunfei Liao, Lulu Chen, Yong Feng, Jacson K. Shen, Yan Gao, Gregory Michael Cote, Edwin Choy, David C. Harmon, Henry J. Mankin, Francis John Hornicek et al. · 2017 · Oncotarget
  37. Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy
    David James Pinato, Robert J. Shiner, Solomon D T White, James R. Black, Pritesh S. Trivedi, Justin Stebbing, Rohini Sharma, Francesco Angelo Mauri · 2016 · OncoImmunology
  38. Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition
    Jared M. Newton, Aurélie Hanoteau, Hsuan‐Chen Liu, Angelina Gaspero, Falguni Parikh, Robyn D. Gartrell, Thomas D. Hart, Damya Laoui, Jo A. Van Ginderachter, Neeraja Dharmaraj et al. · 2019 · Journal for ImmunoTherapy of Cancer
  39. Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
    Juwon Lee, Youngjin Han, Wenyu Wang, HyunA Jo, Heeyeon Kim, Soochi Kim, Kyung‐Min Yang, Seong‐Jin Kim, Danny N. Dhanasekaran, Yong Sang Song · 2021 · Biomolecules
  40. Conjunctival melanoma: New insights in tumour genetics and immunology, leading to new therapeutic options
    Niels J. Brouwer, Robert M. Verdijk, Steffen Heegaard, Marina Marinkovic, Bita Esmaeli, Martine Johanna Jager · 2021 · Progress in Retinal and Eye Research
  41. Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A Phase II Trial
    Hielke Martijn de Vries, Tynisha S. Rafael, Alberto Gil-Jimenez, Jeantine M. de Feijter, Elise M. Bekers, Elsbeth van der Laan, Marta López‐Yurda, Erik Hooijberg, Annegien Broeks, Dennis D. G. C. Peters et al. · 2023 · Journal of Clinical Oncology
  42. Deep learning-based image analysis methods for brightfield-acquired multiplex immunohistochemistry images
    Danielle Fassler, Shahira Abousamra, Rajarsi Gupta, Chao Chen, Maozheng Zhao, David Paredes, Syeda Areeha Batool, Beatrice S. Knudsen, Luisa F. Escobar‐Hoyos, Kenneth Reed Shroyer et al. · 2020 · Diagnostic Pathology
  43. PD ‐L1 expression in extrahepatic cholangiocarcinoma
    Dirk H. Walter, Eva Maria Herrmann, Andreas Anton Schnitzbauer, Stefan Zeuzem, Martin Leo Hansmann, Jan Peveling‐Oberhag, Sylvia Hartmann · 2017 · Histopathology
  44. Biomarkers of response to immune checkpoint blockade in cancer treatment
    Takeo Fujii, Aung Naing, Christian D. Rolfo, Joud Hajjar · 2018 · Critical Reviews in Oncology/Hematology
  45. 18F-FDG PET/CT in non-small-cell lung cancer patients
    Laura Evangelista, Lea Cuppari, Jessica Menis, Laura Bonanno, Pasquale Reccia, Stefano Frega, Giulia Pasello · 2019 · Nuclear Medicine Communications
  46. Cell Tracking in Cancer Immunotherapy
    Justine Perrin, Marisa Capitao, Marie Mougin‐Degraef, François Guérard, Alain Faivre-Chauvet, Latifa Rbah‐Vidal, Joëlle Gaschet, Yannick Guilloux, Françoise Kraeber‐Bodéré, Michel Chérel et al. · 2020 · Frontiers in Medicine
  47. Cancer of Unknown Primary in the Molecular Era
    Shumei Kato, Ahmed Alsafar, Vighnesh Walavalkar, John Daniel Hainsworth, Razelle Kurzrock · 2021 · Trends in cancer
  48. Evaluating the impact of age on immune checkpoint therapy biomarkers
    Rossin Erbe, Zheyu Wang, Sharon K. Wu, Joanne Xiu, Neeha Zaidi, Jennifer La, David P. Tuck, Nathanael R. Fillmore, Nicolás A. Giraldo, Michael J. Topper et al. · 2021 · Cell Reports
  49. The potential role of vitamin C in empowering cancer immunotherapy
    Takwa Bedhiafi, Varghese Philipose Inchakalody, Queenie Fernandes, Sarra Mestiri, Nashiru Billa, Shahab Uddin M.S., Maysaloun Merhi, Said Dermime · 2021 · Biomedicine & Pharmacotherapy
  50. CAR‐T cell therapy for lung cancer: Potential and perspective
    Long Chen, Fukun Chen, Jindan Li, Yongzhu Pu, Conghui Yang, Yue Wang, Yujie Lei, Yunchao Huang · 2022 · Thoracic Cancer
  51. Associations among pretreatment tumor necrosis and the expression of HIF-1α and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof
    Tseng‐Cheng Chen, Chen‐Tu Wu, Cheng‐Ping Wang, Wan‐Lun Hsu, Tsung‐Lin Yang, Pei‐Jen Lou, Jenq‐Yuh Ko, Yih‐Leong Chang · 2015 · Oral Oncology
  52. Analysis ofMDM2Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies
    Shumei Kato, Jeffrey S. Ross, Laurie M. Gay, Farshid Dayyani, Jason Roszik, Vivek Subbiah, Razelle Kurzrock · 2018 · JCO Precision Oncology
  53. Extracellular vesicle PD‐L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies
    Liu, Jiaxing, Peng, Xueqiang, Yang, Shuo, Li, Xinyu, Huang, Mingyao, Wei, Shibo, Zhang, Sheng, He, Guangpeng, Zheng, Hongyu, Fan, Qing et al. · 2022 · Cell Communication and Signaling
  54. The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors
    Daniel E. Meyers, Igor Stukalin, Isabelle A. Vallerand, Ryan T. Lewinson, Aleksi Emil Suo, Michelle Liane Dean, Scott A. North, Aliyah Pabani, Tina Cheng, Daniel Yick Chin Heng et al. · 2019 · Cancers
  55. News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors
    Ombretta Melaiu, Valeria Lucarini, Roberto Giovannoni, Doriana Fruci, Federica Gemignani · 2020 · Seminars in Cancer Biology
  56. Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction
    Mojun Zhu, Chunhua Chen, Nathan R. Foster, Christopher Hartley, Taofic Mounajjed, Marcela A. Salomao, Briant F. Fruth, Staci E. Beamer, Yohan Kim, Susan M. Harrington et al. · 2022 · Clinical Cancer Research
  57. The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression
    C.M. Kim, Jii Bum Lee, Sang Joon Shin, Joong Bae Ahn, Min‐Ji Lee, Han Sang Kim · 2022 · ESMO Open
  58. High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations
    Amélie Boichard, Igor F. Tsigelny, Razelle Kurzrock · 2017 · OncoImmunology
  59. Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments
    Yang Du, Xiaolong Liang, Yuan Li, Ting Sun, Huadan Xue, Zhengyu Jin, Jie Tian · 2017 · Cancer Letters
  60. The Significance of the PD-L1 Expression in Non–Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers
    Kazuki Takada, Gouji Toyokawa, Fumihiro Shoji, Tatsuro Okamoto, Yoshihiko Maehara · 2017 · Clinical Lung Cancer
  61. Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy
    Iris Lodewijk, Sandra P Nunes, Rui Henrique, Cármen Jerónimo, Marta Dueñas, Jesús María Paramio · 2021 · Clinical Epigenetics
  62. Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer
    Maximilian Boesch, Florent Baty, Werner C. Albrich, Lukas Flatz, Regulo Rodriguez, Sacha I. Rothschild, Markus Joerger, Martin Früh, Martin Hugo Brutsche · 2021 · OncoImmunology
  63. Computational immunogenomic approaches to predict response to cancer immunotherapies
    Venkateswar Addala, Felicity Newell, John V. Pearson, ALEC JAMES REDWOOD, Bruce W.S. Robinson, Jenette Creaney, Nicola Waddell · 2023 · Nature Reviews Clinical Oncology
  64. Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non–Small Cell Lung Carcinoma Tumors
    Edwin Roger Parra, Pamela Andrea Villalobos, Jiexin Zhang, Carmen Behrens, Barbara Mino, Stephen G. Swisher, Boris Sepesi, Annika Weissferdt, Neda Kalhor, John Victor Heymach et al. · 2018 · Journal of Thoracic Oncology
  65. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette–Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma
    Jessica Da Gama Duarte, Sagun Parakh, Miles Cameron Andrews, Katherine Woods, Anupama Pasam, Candani S. A. Tutuka, Simone Ostrouska, Jonathan Michael Blackburn, Andreas Behren, Jonathan Simon Cebon · 2018 · Frontiers in Immunology
  66. High IDO ‐1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma
    Andreas Seeber, Gerald Klinglmair, Josef Fritz, Fabian Steinkohl, Kai‐Christian Zimmer, Friedrich Aigner, Wolfgang Horninger, Günther A. Gastl, Bettina Gudrun Zelger, Andrea Brunner et al. · 2018 · Cancer Science
  67. Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society
    Erik Thunnissen, Timothy Craig Allen, Julien Adam, Dara L. Aisner, Mary Beth Beasley, Alain Borczuk, Philip T. Cagle, Vera Luíza Capelozzi, Wendy A. Cooper, Lida P. Hariri et al. · 2017 · Archives of Pathology & Laboratory Medicine
  68. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer
    Jieun Lee, Dong-Min Kim, Ah-Won Lee · 2018 · Cancer Research and Treatment
  69. PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer
    Ana Bocanegra, G. Fernández-Hinojal, Miren Zuazo, Hugo Arasanz, María Jesús García-Granda, Carlos Hernandez, María Ibáñez-Vea, Berta Hernández‐Marín, Maite Martínez-Aguillo, María José Lecumberri et al. · 2019 · International Journal of Molecular Sciences
  70. Development of [ 18 F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide
    Wojciech G. Lesniak, Ronnie C. Mease, Samit Chatterjee, Dhiraj Kumar, Ala Lisok, Bryan L. Wharram, Venkateswara Rao Kalagadda, Leisha A. Emens, Martin G. Pomper, Sridhar Nimmagadda · 2019 · Molecular Imaging
  71. Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
    Alessandra Raimondi, Pierangela Sepe, Emma Zattarin, Alessia Mennitto, Marco Stellato, Mélanie Claps, Valentina Guadalupi, Elena Verzoni, Filippo de Braud, Giuseppe Procopio · 2020 · Frontiers in Oncology
  72. Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer
    Won-Chul Lee, Lixia Diao, Jing Wang, Jianhua Zhang, Emily B. Roarty, Susan Varghese, Chi-Wan B. Chow, Junya Fujimoto, Carmen Behrens, Tina Cascone et al. · 2018 · Modern Pathology
  73. PD-L1 Expression in Human Breast Cancer Stem Cells Is Epigenetically Regulated through Posttranslational Histone Modifications
    Pramod Darvin, Varun Sasidharan Nair, Eyad Elkord · 2019 · Journal of Oncology
  74. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma
    Kazuki Takada, Tatsuro Okamoto, Gouji Toyokawa, Yuka Kozuma, Taichi Matsubara, Naoki Haratake, Takaki Akamine, Shinkichi Takamori, Masakazu Katsura, Fumihiro Shoji et al. · 2016 · Lung Cancer
  75. The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study
    Theodoros Karantanos, Styliani Karanika, Bhavna Seth, Gretchen A. Gignac · 2018 · Clinical & Translational Oncology
  76. Current status and quality of radiomic studies for predicting immunotherapy response and outcome in patients with non-small cell lung cancer: a systematic review and meta-analysis
    Qiuying Chen, Lu Zhang, Xiaokai Mo, Jingjing You, Luyan Chen, Fang Jin, Fei Wang, Zhe Jin, Bin Zhang, Shuixing Zhang · 2021 · European Journal of Nuclear Medicine and Molecular Imaging
  77. Immunotherapy in Gastrointestinal Cancers
    Letizia Procaccio, Marta Schirripa, Matteo Fassan, Loredana Vecchione, Francesca Bergamo, Alessandra Anna Prete, Rossana Intini, Chiara Manai, Vincenzo Dadduzio, Alice Boscolo et al. · 2017 · BioMed Research International
  78. Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature
    Francesco Sabbatino, Antonio Marra, Luigi Liguori, Giosuè Scognamiglio, Celeste Fusciello, Gerardo Botti, Soldano Ferrone, Stefano Pepe · 2018 · Journal for ImmunoTherapy of Cancer
  79. The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy
    Minsu Kwon, Hanul Jung, Gi‐Hoon Nam, In-San Kim · 2021 · Journal of Controlled Release
  80. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way
    Xiaolu Yu, Yiru Long, Binfan Chen, Yongliang Tong, Mengwen Shan, Xiaomin Jia, Chao Hu, Meng Liu, Ji Ying Zhou, Feng Tang et al. · 2022 · Journal for ImmunoTherapy of Cancer
  81. Epigenetic Modifiers in Immunotherapy: a Focus on Checkpoint Inhibitors
    Manuela Terranova-Barberio, Scott Thomas, Pamela N. Münster · 2016 · Immunotherapy
  82. The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer
    Leora Horn, Martin Reck, David Robert Spigel · 2016 · The Oncologist
  83. PD-L1 Expression and Immune Cell Infiltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity
    Martina Ferrata, Arno Schad, S. Zimmer, Thomas J. Musholt, Katharina Bahr‐Hamm, Julian Kuenzel, Sven Becker, Erik Springer, Wilfried Roth, Matthias M. Weber et al. · 2019 · Frontiers in Oncology
  84. Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study
    Jianliang Yang, Lihou Dong, Sheng Yang, Xiaohong Han, Ying Han, Shiyu Jiang, Jiarui Yao, Zhishang Zhang, Shuxiang Zhang, Peng Liu et al. · 2020 · European Journal of Cancer
  85. Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival
    Daniel J. Boffa, Ryon P. Graf, Michelle C. Salazar, Jessica R. Hoag, David M. Lu, Rachel Krupa, Jessica E. Louw, Lyndsey Dugan, Yipeng Wang, Mark Andrew Landers et al. · 2017 · Cancer Epidemiology Biomarkers & Prevention
  86. Characterization of human cancer xenografts in humanized mice
    Jonathan Rios‐Doria, Christina Stevens, Christopher J. Maddage, Kerri Lasky, Holly K. Koblish · 2020 · Journal for ImmunoTherapy of Cancer
  87. Imaging-Based Prediction of Molecular Therapy Targets in NSCLC by Radiogenomics and AI Approaches: A Systematic Review
    Gaia Ninatti, Margarita Kirienko, Emanuele Neri, Martina Sollini, Arturo Chiti · 2020 · Diagnostics
  88. SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer
    Gregory P. Botta, Shumei Kato, Hitendra Patel, Paul Timothy Fanta, Suzanna Lee, Ryosuke Okamura, Razelle Kurzrock · 2021 · JCI Insight
  89. Combining immunotherapy and radiotherapy in lung cancer
    Neeraj Bhalla, Rachel C. Brooker, Michael Brada · 2018 · Journal of Thoracic Disease
  90. Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells
    Lai, Qi, Wang, Haiyong, Li, Angui, Xu, Yinhui, Tang, Liang, Chen, Qiang, Zhang, Chunfang, Gao, Yang, Song, Jianfei, Du, Zhenzong · 2018 · Oncogene
  91. A simple method to estimate prediction intervals and predictive distributions: Summarizing meta‐analyses beyond means and confidence intervals
    Chia‐Chun Wang, Wen‐Chung Lee · 2019 · Research Synthesis Methods
  92. Extracellular vesicles and oncogenic signaling
    Antonia Schubert, Michael Boutros · 2020 · Molecular Oncology
  93. The evolving role of immune cells in prostate cancer
    Chao Wang, Yan Zhang, Wei‐Qiang Gao · 2021 · Cancer Letters
  94. Cancer-associated oxidoreductase ERO1-α promotes immune escape through up-regulation of PD-L1 in human breast cancer
    Tsutomu Tanaka, Goro Kutomi, Toshimitsu Kajiwara, Kazuharu Kukita, Vitaly Kochin, Takayuki Kanaseki, Tomohide Tsukahara, Yoshihiko Hirohashi, Toshihiko Torigoe, Yoshiharu Okamoto et al. · 2017 · Oncotarget
  95. Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?
    Hussain, Nadiya, Naeem, Muntaha, Pinato, David J. · 2021 · Human Vaccines & Immunotherapeutics
  96. Immuno-PET imaging of 68Ga-labeled nanobody Nb109 for dynamic monitoring the PD-L1 expression in cancers
    Qingzhu Liu, Lei Jiang, Ke Li, Hang Li, Gao‐Chao Lv, Jianguo Lin, Ling Qiu · 2021 · Cancer Immunology Immunotherapy
  97. Immune profiling and prognostic model of pancreatic cancer using quantitative pathology and single-cell RNA sequencing
    Kai Chen, Qi Wang, Xinxin Liu, Xiaodong Tian, Aimei Dong, Yinmo Yang · 2023 · Journal of Translational Medicine
  98. microRNA: The Impact on Cancer Stemness and Therapeutic Resistance
    Xueqiao Jiao, Xianling Qian, Longyuan Wu, Bo Li, Yi Wang, Xinyu Kong, Lixia Xiong · 2019 · Cells
  99. Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges
    Sridhar Nimmagadda · 2020 · Cancers
  100. Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers
    Vito Amodio, Gianluca Mauri, Nicole Megan Reilly, Andrea Sartore Bianchi, Salvatore Siena, Alberto Bardelli, Giovanni Germano · 2021 · Cancers